Market Sectors
Latest News
Thursday, January 26 2012. UK based BACTEST Ltd. today announced that it had closed a £900k funding round led by the Low Carbon Innovation Fund (LCIF), managed by Turquoise International, which invested £300k in BACTEST.
Bactest has created a wholly owned subsidiary to exploit its proprietory platform CYTOMAIA in the Human Health Sector. The new company GEMINI Diagnostics Ltd will focus on human clinical applications of CYTOMAIA.
Market Sectors
The technology platform that Bactest has developed (CYTOMAIA)operates as a sensitive, precision respirometer. Detection of metabolic activity is determined by sensitive pressure measurements relating to gaseous exchanges as a result of microbial respiration.
Within the research field there a countless opportunities where application may be found for such a broadly versatile technology.
CYTOMAIA has multiple applications in the rapidly expanding environmental sector including toxicity testing of effluent, and measurement of metabolic activity in activated sludges for improved process control within water treatment plants. Anearobic digestion offers a further application where potential improvements may be possible with closer monitoring and control of microbial processes.
The food industry has significant issues with microbial contamination and spoilage but has limited tools available to monitor this in “real time”.
Considerable opportunities exist for rapid, simple, localised testing in the food and industrial microbiology sectors including raw materials and final product testing as well as process and hygiene monitoring.
Besides being a low cost instrument for veterinary surgeries seeking the ability to undertake animal blood tests, there is the possibility of developing specific tests such as those for Johne’s disease in cattle
The product range which will be launched under the "GEMINI" name represents a totally unique and innovative approach to the issues facing microbiologists, clinicians and Hospital Managers alike.
